New study aims to improve lung cancer treatment for black patients

NCT ID NCT06745882

First seen Dec 04, 2025 · Last updated May 07, 2026 · Updated 19 times

Summary

This study looks at how well the drug pembrolizumab (with or without chemotherapy) works in Black patients with advanced non-small cell lung cancer. About 318 participants will be followed to see how long they live or how long the cancer stays under control. The goal is to find markers that predict who benefits most from treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baptist Clinical Research Institute

    RECRUITING

    Memphis, Tennessee, 38120, United States

    Contact

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

  • Montefiore Medical Cancer Center

    RECRUITING

    The Bronx, New York, 10461, United States

    Contact

  • TidalHealth Peninsula Regional

    RECRUITING

    Salisbury, Maryland, 20801, United States

    Contact

Conditions

Explore the condition pages connected to this study.